Rona Laboratories

Rona Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of modular RNA therapeutics. The company leverages its proprietary RI-S (RNAi Integrated Platform) to engineer next-generation small interfering RNA (siRNA) molecules with enhanced stability, potency, and delivery capabilities. Rona's pipeline primarily targets metabolic and cardiovascular diseases, with lead programs focused on PCSK9 for hypercholesterolemia and Factor XI for thrombosis. Beyond liver-targeted therapies, the company is expanding its platform to address unmet needs in central nervous system and ocular disorders. Headquartered in Shanghai with a research hub in San Diego, Rona is backed by prominent life science investors including Lilly Asia Ventures.